IRD
Opus Genetics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$350.05M
P/E Ratio
—
EPS
$-0.80
Beta
0.52
52W High
$5.30
52W Low
$0.65
50-Day MA
$3.90
200-Day MA
$2.21
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.00
PEG Ratio
—
About Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) is an innovative biotechnology company specializing in gene therapies for rare retinal diseases that impact vision. Leveraging cutting-edge research and proprietary gene-editing technologies, Opus aims to fulfill significant unmet medical needs through transformative solutions that restore sight. With a dedicated focus on ocular health, the company is positioned as a frontrunner in the biotech industry, appealing to investors interested in pioneering healthcare advancements. Supported by ongoing clinical trials and strategic collaborations, Opus Genetics is well-equipped to improve patient outcomes while generating substantial value for its stakeholders.
Fundamentals
| Revenue (TTM) | $14.20M |
| Gross Profit (TTM) | $-16.62M |
| EBITDA | $-38.55M |
| Operating Margin | -296.30% |
| Return on Equity | -242.40% |
| Return on Assets | -55.40% |
| Revenue/Share (TTM) | $0.23 |
| Book Value | $0.22 |
| Price-to-Book | 21.07 |
| Price-to-Sales (TTM) | 24.66 |
| EV/Revenue | 19.68 |
| EV/EBITDA | -2.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -10.20% |
| Shares Outstanding | $71.15M |
| Float | $34.82M |
| % Insiders | 14.47% |
| % Institutions | 37.58% |
Analyst Ratings
Consensus ($9.93 target)
1
Strong Buy13
BuyData last updated: 4/8/2026